New Study: Women Live Over a Quarter of Their Lives in Poor Health
Data from the UK shows that the gap between total life expectancy and healthy years for women is widening, reaching 22 years. The causes are cited as a lack of medical research into female diseases, hormonal changes, and socioeconomic inequality.
An insider, I'll say it straight: the news about 22 years of women's lives spent in poor health is not medical statistics—it's a detonator for the most commercially undervalued market on the planet. While the average person reads these figures with anxiety, venture capital funds and biotech corporations see not a crisis, but the final confirmation of the fattest investment case of the decade.
The Gist: What's Really Happening
This isn't about health. It's about institutional investors finally getting mathematical proof that women's health beyond reproduction is not niche charity, but a market with turnover approaching a trillion. Why am I so sure? Because on the very same day the ONS data on 22 years of unhealthy life is published, the World Economic Forum in Davos releases a report stating in black and white: targeted closure of four "female" pathologies (cardiovascular, bone, mental, and menopausal disorders) will unlock economic value exceeding $100 billion in the US market alone by 2030. This isn't social welfare. This is the new oil.
Timeline and Context
January 2025. The NIH in the US gets its first real budget cut in a decade. The Republican majority begins scanning grants for the word "women," withdrawing research not related to oncology or reproduction. February 2025. The FemTech venture market reacts instantly: private funds, including structures from Goldman Sachs, realize the government is pulling out of this science and start buying up startups working on "forgotten" topics—endometriosis, autoimmune pathologies, and menopause.
January 20, 2026. The WEF publishes the first-ever Women's Health Investment Outlook. The document states that only 6% of all private medical investments go to women's health, and 90% of that is locked in oncology and fertility. Cardiology, osteoporosis, Alzheimer's in women—virtually unfunded.
March 2026. A Menoveda study records shocking economic losses—$150 billion annually due to untreated menopause and women dropping out of the economy. April 2026. The Health Foundation publishes data: in Britain, healthy life expectancy has fallen below 61 years, and the gap between rich and poor areas for women has reached 20.3 years. This means the retirement age (66) has become an unattainable dream for the majority.
May 2026. British government actuaries record a deadly nosedive: women live an average of 83 years, but the last 22 of them are not life, but survival in illness. Women from poor areas of England spend more than 30 years in a state of "ill health."
Who Wins and Who Loses
The global FemTech sector wins. Its current size is estimated at $47–55 billion with a growth forecast to $120–130 billion by 2030 (CAGR at least 15–20%). This is not the future; it's the present. Startups producing "smart" rings and bracelets that track vasomotor symptoms of menopause are becoming M&A targets for giants like Apple and Amazon.
Longevity clinics win. They get a blank check to sell expensive protocols for menopausal hormone therapy, peptide complexes, and lifestyle coaching for women 40+. Whoever first skillfully packages "menopause management" as biohacking, not a disease, will skim the cream off the market.
Government budgets lose. Governments unable to cope with the demographic pit will face a mass exodus of the female workforce aged 50+. Canada has already calculated: just untreated menopause costs businesses $3.5 billion annually in lost productivity. Multiply that by the G7 economies, and you get a figure comparable to military budgets.
What the Media Isn't Saying
The key insight: the failure of women's health is not a biological error, but a design flaw in pharmaceutical science. Medical protocols have been created for decades based on male physiology. Women are dying en masse from cardiovascular diseases with atypical symptoms that doctors simply don't recognize. Direct and indirect losses from CVD in women already exceed $500 billion per year in the US alone.
The second point that goes unmentioned: the venture market is flush with cash but can't spend it. At the start of 2026, investments in women's health are stuck at the Series A stage. Why? Because there's no government validation. Without the NIH and NHS, which for decades played the role of a "seal of quality" for complex medical startups, private funds are afraid to enter endometriosis or osteoporosis. An absurd situation arises: there's record money, but it's sitting idle.
Forecast: Next 30 Days and 90 Days
In the next 30 days, expect personnel scandals. Major US hospices and nursing homes will start leaking about a catastrophic shortage of care for elderly women. Where families used to help, a demographic hole now gapes.
Within a 90-day horizon, with the start of the new fiscal year in the US and Europe, we will see a transition from the "hype" stage to the "regulation" stage in the FemTech market. The HHS and NHS will publish requirements for the evidence base for digital women's health tools. Platforms promising to "cure menopause" without proof will start rapidly losing ground. Conversely, pharma giants will begin aggressively buying up biotechs with real patents for targeted drugs.
The bottom line: 22 years of female suffering is not a social catastrophe—it's the most powerful capitalization driver of the next decade. If you're in business, look at menopause and women's cardiology. If you're in politics, look at demographics. But if you're an ordinary person, just remember: the state hasn't designed a safety net for these years. You will buy your health on the open market. And the price will rise.
— Editorial Team
